<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04629339</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 86550-203</org_study_id>
    <nct_id>NCT04629339</nct_id>
  </id_info>
  <brief_title>Study of INCB086550 in Select Solid Tumors</brief_title>
  <official_title>A Phase 2 Study of INCB086550 (Oral PD-L1 Inhibitor) in Participants Who Are Immune Checkpoint Inhibitor-Naïve With Selected Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, nonrandomized study to evaluate the efficacy and safety of INCB086550, a&#xD;
      first-in-class oral inhibitor of PD-L1, as initial immune checkpoint inhibitor therapy in&#xD;
      participants with select solid tumors&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2021</start_date>
  <completion_date type="Anticipated">February 19, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 14, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Defined as the percentage of participants with a best overall response of CR or PR confirmed by at least 1 repeat assessment ≥ 28 days later according to RECIST v1.1 as determined by the investigator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Defined as the percentage of participants with a best overall response of CR or PR confirmed by at least 1 repeat assessment ≥ 28 days later, or SD for ≥ 12 weeks, by investigator assessment per RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Defined as the time from the earliest date of CR or PR confirmed by at least 1 repeat assessment ≥ 28 days later until the earliest date of disease progression by investigator assessment per RECIST v1.1, or death due to any cause, if occurring sooner than progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of INCB86550 as Assessed by Number of Participants With a TEAE</measure>
    <time_frame>up to 2 years</time_frame>
    <description>TEAE defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Urothelial Cancer</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>INCB086550</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB086550 will be administered orally twice a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB086550</intervention_name>
    <description>INCB086550 will be administered orally twice a day.</description>
    <arm_group_label>INCB086550</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to comprehend and willingness to sign a written ICF for the study.&#xD;
&#xD;
          -  Participants with following tumor types : non small cell lung cancer, renal cell&#xD;
             carcinoma, urothelial carcinoma, hepatocellular carcinoma and melanoma&#xD;
&#xD;
          -  Measurable disease per RECIST v1.1.&#xD;
&#xD;
          -  ECOG performance status of 0 to 1 for all tumor types. Urothelial carcinoma allows&#xD;
             ECOG of 0 to 2.&#xD;
&#xD;
          -  Histologically or cytologically confirmed disease-specific diagnosis as per protocol.&#xD;
&#xD;
          -  Willingness to avoid pregnancy or fathering children&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior receipt of an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or treatment with an&#xD;
             immune modulator (eg, CTLA-4, GITR, LAG3, TIM3, OX40, ICOS, IL2, 4-1BB, CAR-T).&#xD;
&#xD;
          -  Receipt of any anticancer therapy or participation in another interventional clinical&#xD;
             study.&#xD;
&#xD;
          -  Radiotherapy within 14 days of first dose of study treatment.&#xD;
&#xD;
          -  Concomitant treatment with moderate and potent CYP3A4/CYP3A5 inhibitors or inducers.&#xD;
&#xD;
          -  Toxicity of prior therapy that has not recovered to ≤ Grade 1 or baseline (with the&#xD;
             exception of anemia not requiring transfusion support and any grade of alopecia).&#xD;
             Endocrinopathy, if well-managed, is not exclusionary and should be discussed with the&#xD;
             medical monitor.&#xD;
&#xD;
          -  Participant has not recovered adequately from toxicities and/or complications from&#xD;
             surgical intervention before starting study drug.&#xD;
&#xD;
          -  Participants with laboratory values outside of protocol defined ranges Active&#xD;
             malignancy of a type not included in the study population requiring treatment.&#xD;
&#xD;
          -  Active autoimmune disease requiring systemic immunosuppression in excess of&#xD;
             physiologic maintenance doses of corticosteroids (&gt; 10 mg of prednisone or&#xD;
             equivalent).&#xD;
&#xD;
          -  Evidence of interstitial lung disease or active, noninfectious pneumonitis.&#xD;
&#xD;
          -  Untreated or known active CNS metastases and/or carcinomatous meningitis.&#xD;
&#xD;
          -  With the exception of participants with HCC, known active HAV, HBV, or HCV infection,&#xD;
             as defined by elevated transaminases with the following serology: positivity for HAV&#xD;
             IgM antibody, anti-HCV, anti-HBc IgG or IgM, or HBsAg (in the absence of prior&#xD;
             immunization).&#xD;
&#xD;
          -  Active infection requiring systemic therapy.&#xD;
&#xD;
          -  Receipt of systemic antibiotics within 28 days of first dose of study treatment&#xD;
&#xD;
          -  Probiotic usage during screening and throughout the study treatment period.&#xD;
&#xD;
          -  Participants who are known to be HIV-positive.&#xD;
&#xD;
          -  Participants with impaired cardiac function or clinically significant cardiac disease.&#xD;
&#xD;
          -  History or presence of an ECG finding that, in the investigator's opinion, is&#xD;
             clinically meaningful.&#xD;
&#xD;
          -  Female participant is pregnant or breastfeeding within the projected duration of the&#xD;
             study, starting with the screening visit through the 90-day safety follow-up, or male&#xD;
             participant is expecting to conceive or father children within the projected duration&#xD;
             of the study, starting with the screening visit through 100 days after the last dose&#xD;
             of study treatment.&#xD;
&#xD;
          -  Has received a live vaccine within 90 days of the planned start of study drug.&#xD;
&#xD;
          -  Current use of a prohibited medication as described in protocol.&#xD;
&#xD;
          -  Life expectancy &lt; 3 months.&#xD;
&#xD;
          -  Known hypersensitivity or severe reaction to any component of study drug or&#xD;
             formulation components.&#xD;
&#xD;
          -  History of organ transplant, including allogeneic stem cell transplantation.&#xD;
&#xD;
          -  Inability to swallow tablets or any condition of the upper gastrointestinal tract that&#xD;
             precludes administration of oral medications.&#xD;
&#xD;
          -  Any condition that would, in the investigator's judgment, interfere with full&#xD;
             participation in the study, including administration of study drug and attending&#xD;
             required study visits; pose a significant risk to the participant; or interfere with&#xD;
             interpretation of study data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>eumedinfo@incyte.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>COMPLEX ONCOLOGY CENTER ï¿½ BURGAS EOOD</name>
      <address>
        <city>Burgas</city>
        <zip>08000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital For Active Treatment &quot;Dr. Tota Venkova&quot; Jsc</name>
      <address>
        <city>Gabrovo</city>
        <zip>05300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shatod Dr Marko Marko - Varna Ltd</name>
      <address>
        <city>Varna</city>
        <zip>09002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Multifield Clinical Hospital No 4</name>
      <address>
        <city>Dnipro</city>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Communal Non-Profit Enterprise Regional Center of Oncology</name>
      <address>
        <city>Kharkiv</city>
        <zip>61070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ci of Healthcare Regional Clinical Specialized Dispensary of the Radiation Protection</name>
      <address>
        <city>Kharkiv</city>
        <zip>61166</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mi Kryviy Rih Center of Dnipropetrovsk Regional Council</name>
      <address>
        <city>Kryvyi Rih</city>
        <zip>50048</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Volyn Regional Oncological Dispensary</name>
      <address>
        <city>Lutsk</city>
        <zip>43018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rmi Sumy Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Sumy</city>
        <zip>40022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Clinic Innovacia Llc</name>
      <address>
        <city>Vyshhorod</city>
        <zip>07352</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 10, 2020</study_first_submitted>
  <study_first_submitted_qc>November 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>checkpoint inhibitor naive</keyword>
  <keyword>Metastatic</keyword>
  <keyword>PD-L1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.</ipd_time_frame>
    <ipd_access_criteria>Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.incyte.com/our-company/compliance-and-transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

